Login to Your Account



J.P. Morgan Healthcare Conference

Looking Good: Fresh from IPO, Kythera Spins Twin Chin Win

By Randy Osborne
Staff Writer

Tuesday, January 8, 2013
SAN FRANCISCO – With positive Phase III data in hand from European trials and more due this year from U.S. pivotal studies, Kythera Biopharmaceuticals Inc. offered attendees of the J.P. Morgan Healthcare Conference the company's game plan for earnings as "a new entrant into the established market of facial injectables," said Keith Leonard, co-founder, president and CEO.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription